Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01290900 · ClinicalTrials.gov registry record · Phase 1
A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT01290900 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 54 participants.
The verdict
NCT01290900, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
This is a single dose study in healthy male volunteers to investigate the effect of high doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval
Interventions
- DRUG Moxifloxacin
- DRUG Ceftaroline
- DRUG Placebo Infusion
- DRUG NXL104
- DRUG Ceftazidime
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01290900
The ClinicalTrials.gov registry entry for NCT01290900 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Moxifloxacin is the first listed.
NCT01290900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01290900 about?
NCT01290900 is a clinical study titled "A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers". This is a single dose study in healthy male volunteers to investigate the effect of high doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval
What is the current status of trial NCT01290900?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2011-02. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01290900?
The interventions under investigation include: Moxifloxacin (DRUG), Ceftaroline (DRUG), Placebo Infusion (DRUG), NXL104 (DRUG), Ceftazidime (DRUG).
Who is sponsoring clinical trial NCT01290900?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.